CAR T Cell Therapy Market (5th Edition): Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication
Description
CAR T Cell Therapy Market (5th Edition): Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication
The CAR T Cell Therapy Market is valued at USD 4.6 billion in 2024 growing at a CAGR of 20% during the forecast period 2024-2035
Cancer stands as a leading cause of mortality worldwide, with the World Health Organization (WHO) reporting 10 million cancer-related deaths in 2020 alone. Projections suggest that by 2040, the global cancer burden will escalate, adding an estimated 27.5 million new cases, placing immense physical, emotional, and financial strain on affected individuals, families, communities, and national health systems. Currently, conventional treatment modalities such as chemotherapy, radiation therapy, and surgery are utilized for various cancers. However, despite the array of treatment options aimed at controlling disease progression and halting the spread of malignant cells, achieving lasting remission remains challenging. To cater to the limitations of conventional treatments, active initiatives have been launched to develop more targeted anti-cancer therapies. Among these, CAR T cell therapies have emerged as a promising option due to their ability to eliminate tumor cells with minimal treatment-related side effects. Immunotherapies leverage the body's immune system or its components to combat cancer. Various classes of immunotherapies, including therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors, and certain whole cell-based therapies, have emerged as an alternative for cancer management and treatment.
CAR-T cell therapy, a recent addition to anticancer interventions, has shown significant success alongside targeted antibody-based therapeutics like monoclonal and conjugated antibodies. This highly specific form of cell therapy, harnessing the versatile effector machinery of the human immune system, has revolutionized cancer treatment globally. Ongoing research in this field continues to uncover novel molecular targets, bolstering the research pipelines of companies in this domain. With a growing number of CAR T cell therapies under development and entering the market, the CAR T cell therapy market is poised to become one of the most valuable segments within the biopharmaceutical industry.
Key Market Segments
Target Indication
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Generalized Myasthenia Gravis
Hodgkin's Lymphoma
Multiple Myeloma
Non-Hodgkin's Lymphoma
Ovarian Cancer
Renal Cell Carcinoma
Others
Target Antigen
CD19
BCMA
CD19 / CD22
Others
Key Geographical Regions
North America
Europe
Asia-Pacific
Latin America
Middle East and North Africa
Rest of the World
Research Coverage:
A detailed analysis of the current market landscape of CAR-T cell therapies with respect to the type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR T cell therapy. Further, this chapter also includes developer landscape analysis based on the relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia-Pacific).
Comprehensive assessment of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR T cell therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
A comprehensive assessment of the completed, ongoing and planned clinical studies related to CAR T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
An insightful analysis highlighting the key opinion leaders (KOLs) featuring an assessment of the principal investigators of clinical trials related to CAR-T therapies, considering them to be KOLs, who are actively involved in R&D of CAR T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
Elaborate company profiles of leading players in this domain. Each company profile includes a company overview and brief description of the product portfolio, technology portfolio, recent developments related to CAR-T cell therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
An analysis of different types of partnership that have been inked between several stakeholders in this domain, on various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and therapy candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
An analysis of the funding and investment analysis that have been made into CAR T cell therapy companies that have proprietary therapies / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
An in-depth analysis of patents related to CAR T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents filed / granted) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
An elaborate assessment of various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell therapy that is likely to be marketed in the coming years.
An in-depth analysis of various factors that can influence the growth of CAR T cell therapy market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
A detailed estimate of the current market size, opportunity and the future growth potential of the CAR T cell therapy market over the next 12 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within this market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Comprehensive predictions of the current and future CAR T cell therapy market across type of target indication, such as non-Hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma).
Comprehensive projections of the current and future CAR T-cell therapy market across type of target antigen, such as CD19, BCMA, CD19 / CD22 and others.
Detailed projections of the current and future CAR T cell therapy market across leading players.
Detailed projections of the current and future CAR T-cell therapy market across key geographical regions, such as North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World.
A review of the key promotional strategies being adopted by the developers of the approved CAR T cell therapies, namely Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™), Ciltacabtagene Autoleucel (CARVYKTI™) and others.
Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the CAR T Cell Therapy Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Leading Market Companies
Alaunos Therapeutics
Autolus
Abelzeta Pharma
Bluebird Bio
Bristol Myers Squibb
Carsgen Therapeutics
Cellectis
Gilead Sciences
Innovative Cellular Therapeutics
Kuur Therapeutics
Noile-Immune Biotech
Novartis
Shanghai GeneChem
Sinobioway Cell Therapy
Takara Bio
Wellington Zhaotai Therapies
Table of Contents
598 Pages
- 1. Preface
- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
- 2. Research Methodology
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. Covid Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation
- 3. Economic And Other Project Specific Considerations
- 3.1. Chapter Overview
- 3.2. Market Dynamics
- 3.2.1. Time Period
- 3.2.1.1. Historical Trends
- 3.2.1.2. Current And Forecasted Estimates
- 3.2.2. Currency Coverage
- 3.2.2.1. Overview Of Major Currencies Affecting The Market
- 3.2.2.2. Impact Of Currency Fluctuations On The Industry
- 3.2.3. Foreign Exchange Impact
- 3.2.3.1. Evaluation Of Foreign Exchange Rates And Their Impact On Market
- 3.2.3.2. Strategies For Mitigating Foreign Exchange Risk
- 3.2.4. Recession
- 3.2.4.1. Historical Analysis Of Past Recessions And Lessons Learnt
- 3.2.4.2. Assessment Of Current Economic Conditions And Potential Impact On The Market
- 3.2.5. Inflation
- 3.2.5.1. Measurement And Analysis Of Inflationary Pressures In The Economy
- 3.2.5.2. Potential Impact Of Inflation On The Market Evolution
- 4. Executive Summary
- 5. Introduction
- 5.1. Chapter Overview
- 5.2. Overview Of T-cell Immunotherapies
- 5.2.1. Historical Evolution
- 5.2.2. Key Considerations For Developing T-cell Immunotherapies
- 5.2.3. Strategies Employed For The Redirection Of T-cells
- 5.2.4. Manufacturing Of Engineered T-cells
- 5.3. Chimeric Antigen Receptor T-cell (Car-t) Therapy
- 5.3.1. Development History
- 5.3.2. Structure Of Car
- 5.3.2.1. Ectodomain
- 5.3.2.2. Transmembrane (Tm) Domain
- 5.3.2.3. Endodomain
- 5.3.3. Development Of Car-t Cells
- 5.3.4. Universal Car-t Cells
- 5.3.5. Route Of Administration
- 5.3.6. Challenges Associated With Car-t Cell Therapies
- 5.3.6.1. Competitive Risks
- 5.3.6.2. Clinical Risks
- 5.3.6.3. Regulatory Risks
- 5.3.6.4. Commercial Risks
- 5.4. Concluding Remarks
- 6. Car-t Cell Therapies: Market Landscape
- 6.1. Chapter Overview
- 6.2. Car-t Cell Therapies: Market Landscape
- 6.2.2. Analysis By Phase Of Development
- 6.2.3. Analysis By Type Of Therapy
- 6.2.4. Analysis By Therapeutic Area
- 6.2.5. Analysis By Phase Of Development And Therapeutic Area
- 6.2.6. Analysis By Key Target Indication
- 6.2.7. Analysis By Key Target Antigen
- 6.2.8. Analysis By Source Of T-cells
- 6.2.9. Analysis By Phase Of Development And Source Of T-cells
- 6.2.10. Analysis By Route Of Administration
- 6.2.11. Analysis By Dosing Frequency
- 6.2.12. Analysis By Target Patient Population
- 6.2.13. Most Active Industry Players: Analysis By Number Of Therapies
- 6.2.14. Most Active Non-industry Players: Analysis By Number Of Therapies
- 6.3. Car-t Cell Therapies: Overall Developer Landscape
- 6.3.1. Analysis By Year Of Establishment
- 6.3.2. Analysis By Company Size
- 6.3.3. Analysis By Location Of Headquarters
- 7. Key Insights
- 7.1. Chapter Overview
- 7.2. Car-t Cell Therapies: Competitive Analysis Of Popular Target Antigens
- 7.2.1. Popular Targets Related To Hematological Malignancies
- 7.2.2. Popular Targets Related To Solid Tumors
- 7.3. Car-t Therapies: Car Construct Analysis
- 7.3.1. Analysis By Generation Of Car
- 7.3.2. Analysis By Type Of Scfv Antibody
- 7.3.3. Analysis By Type Of Virus Used
- 7.3.4. Analysis By Type Of Gene Transfer Method Used
- 7.3.5. Analysis By Type Of Co-stimulatory Domain
- 8. Clinical Trial Analysis
- 8.1. Chapter Overview
- 8.2. Scope And Methodology
- 8.3. Car-t Cell Therapies: Clinical Trial Analysis
- 8.3.1. Analysis By Trial Registration Year
- 8.3.2. Analysis Of Enrolled Patient Population By Trial Registration Year
- 8.3.3. Analysis By Trial Status
- 8.3.4. Analysis By Trial Registration Year And Trial Status
- 8.3.5. Analysis By Trial Phase
- 8.3.6. Analysis Of Enrolled Patient Population By Trial Phase
- 8.3.7. Analysis By Target Patient Population
- 8.3.8. Analysis By Type Of Sponsor / Collaborator
- 8.3.9. Analysis By Study Design
- 8.3.10. Most Active Industry Players: Analysis By Number Of Registered Trials
- 8.3.11. Most Active Non-industry Players: Analysis By Number Of Registered Trials
- 8.3.12. Analysis By Key Focus Area
- 8.3.13. Analysis By Geography
- 9. Key Opinion Leaders
- 9.1. Chapter Overview
- 9.2. Assumptions And Key Parameters
- 9.3. Methodology
- 9.4. Car-t Cell Therapies: Key Opinion Leaders
- 9.4.1. Analysis By Type Of Organization
- 9.4.2. Analysis By Affiliated Organization
- 9.4.3. Analysis By Geographical Location Of Kols
- 9.4.4. Kol Activeness Versus Kol Strength
- 9.4.5. Most Prominent Kols: Analysis By Ra Score
- 9.4.6. Most Prominent Kols: Comparison Of Ra Score And Third-party Score
- 10. Company Profiles
- 10.1. Chapter Overview
- 10.2. Alaunos Therapeutics
- 10.3. Autolus
- 10.4. Bluebird Bio
- 10.5. Bristol Myers Squibb
- 10.6. Carsgen Therapeutics
- 10.7. Cellectis
- 10.8. Abelzeta Pharma
- 10.9. Gilead Sciences
- 10.10. Innovative Cellular Therapeutics
- 10.11. Kuur Therapeutics
- 10.12. Noile-immune Biotech
- 10.13. Novartis
- 10.14. Shanghai Genechem
- 10.15. Sinobioway Cell Therapy
- 10.16. Takara Bio
- 10.17. Wellington Zhaotai Therapies
- 11. Partnerships And Collaborations
- 11.1. Chapter Overview
- 11.2. Partnership Models
- 11.3. Car-t Cell Therapies: Partnerships And Collaborations
- 11.3.1. Analysis By Year Of Partnership
- 11.3.2. Analysis By Type Of Partnership
- 11.3.3. Analysis By Year And Type Of Partnership
- 11.3.4. Analysis By Type Of Partner
- 11.3.5. Most Popular Therapies: Analysis By Number Of Partnerships
- 11.3.6. Most Active Industry Players: Analysis By Number Of Partnerships
- 11.3.7. Most Active Non-industry Players: Analysis By Number Of Partnerships
- 11.3.8. Analysis By Geography
- 11.3.8.1. Intercontinental And Intracontinental Agreements
- 11.3.8.2. International And Local Agreements
- 12. Funding And Investments Analysis
- 12.1. Chapter Overview
- 12.2. Types Of Funding
- 12.3. Car-t Cell Therapies: Funding And Investment Analysis
- 12.3.1. Analysis By Year Of Funding
- 12.3.2. Analysis Of Amount Invested By Year
- 12.3.3. Analysis By Type Of Funding
- 12.3.4. Analysis By Type Of Investor
- 12.3.5. Most Active Players: Analysis By Amount Invested
- 12.3.5. Most Active Players: Analysis By Number Of Funding Instances
- 12.3.7. Most Active Players: Analysis By Amount Invested
- 12.3.8. Most Active Investors: Analysis By Amount Invested
- 12.3.9. Most Active Investors: Analysis By Number Of Funding Instances
- 12.3.10. Analysis By Geography
- 12.3.10.1. Analysis Of Number Of Instances By Geography
- 12.3.10.2. Analysis Of Amount Invested By Geography
- 13. Patent Analysis
- 13.1. Chapter Overview
- 13.2. Scope And Methodology
- 13.3. Car-t Cell Therapies: Patent Analysis
- 13.3.1. Analysis By Patent Publication Year
- 13.3.2. Analysis By Patent Application Year
- 13.3.3. Analysis By Patent Jurisdiction
- 13.3.4. Analysis By Type Of Player
- 13.3.5. Analysis By Cpc Symbols
- 13.3.6. Leading Industry Players: Analysis By Number Of Patents
- 13.3.7. Leading Non-industry Players: Analysis By Number Of Patents
- 13.3.8. Leading Individual Assignees: Analysis By Number Of Patents
- 13.3.9. Patent Benchmarking Analysis
- 13.3.9.1. Analysis By Patent Characteristics
- 13.3.9.2. Patent Valuation
- 13.3.9.3. Leading Patents By Number Of Citations
- 14. Case Study: Cell Therapy Manufacturing
- 14.1. Chapter Overview
- 14.2. Overview Of Cell Therapy Manufacturing
- 14.3. Cell Therapy Manufacturing Models
- 14.3.1. Centralized Manufacturing Model
- 14.3.2. Decentralized Manufacturing Model
- 14.4. Scalability Of Cell Therapy Manufacturing Processes
- 14.4.1. Scale-up
- 14.4.2. Scale-out
- 14.5. Types Of Cell Therapy Manufacturers
- 14.6. Key Challenges Related To Manufacturing Of Cell Therapies
- 14.7. Key Considerations For Cell Therapy Manufacturing
- 14.7.1. Characterization
- 14.7.2. Cost Of Goods
- 14.8. Automation Of Cell Therapy Manufacturing Process
- 14.9. Cell Therapy Manufacturing Supply Chain
- 14.10. Comparison Of Players Having In-house Capabilities And Contract Manufacturers
- 14.11. Regulatory Landscape
- 14.12. Future Perspectives
- 15. Cost Price Analysis
- 15.1 Chapter Overview
- 15.2. Factors Contributing To The High Price Of Cell / Gene Therapies
- 15.3. Pricing Models For T-cell Immunotherapies
- 15.3.1. Based On Associated Costs
- 15.3.2. Based On Availability Of Competing Products
- 15.3.3. Based On Patient Population
- 15.3.4. Based On Opinions Of Industry Experts
- 15.4. Reimbursement Related Considerations For T-cell Immunotherapies
- 15.4.1. Case Study: The National Institute For Health And Care Excellence (Nice) Appraisal Of Car-t Therapies
- 16. Market Impact Analysis: Drivers, Restraints, Opportunities And Challenges
- 16.1. Chapter Overview
- 16.2. Market Drivers
- 16.3. Market Restraints
- 16.4. Market Opportunities
- 16.5. Market Challenges
- 16.6. Conclusion
- 17. Global Car-t Cell Therapy Market
- 17.1. Chapter Overview
- 17.2. Key Assumptions And Methodology
- 17.3. Global Car-t Cell Therapy Market, Historical Trends (2018-2023) And Future Estimates (2024-2035), Till 2035
- 17.4. Scenario Analysis
- 17.4.1. Conservative Scenario
- 17.4.2. Optimistic Scenario
- 17.5. Car-t Cell Therapy Market: Drug-wise Sales Forecast, Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 17.6. Key Market Segmentations
- 18. Car-t Cell Therapy Market, By Target Indication
- 18.1. Chapter Overview
- 18.2. Key Assumptions And Methodology
- 18.3. Car-t Cell Therapy Market: Distribution By Target Indication, 2024, 2030 And 2035
- 18.3.1. Car-t Cell Therapy Market For Acute Lymphoblastic Leukemia: Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 18.3.2. Car-t Cell Therapy Market For Chronic Lymphocytic Leukemia: Historical Trends And Future Estimates, Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 18.3.3. Car-t Cell Therapy Market For Multiple Myeloma: Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 18.3.4. Car-t Cell Therapy Market For Non-hodgkin Lymphoma: Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 18.3.5. Car-t Cell Therapy Market For Other Indications: Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 18.6. Data Triangulation And Validation
- 19. Car-t Cell Therapy Market, By Target Antigen
- 19.1. Chapter Overview
- 19.2. Key Assumptions And Methodology
- 19.3. Car-t Cell Therapy Market: Distribution By Target Antigen, 2024, 2030 And 2035
- 19.3.1. Car-t Cell Therapy Market For Cd19: Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 19.3.2. Car-t Cell Therapy Market For Bcma: Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 19.3.3. Car-t Cell Therapy Market For Other Target Antigens: Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 19.4. Data Triangulation And Validation
- 20. Car-t Cell Therapy Market, By Key Players
- 20.1. Chapter Overview
- 20.2. Key Assumptions And Methodology
- 20.3. Car-t Cell Therapy Market: Distribution By Key Players
- 20.4. Data Triangulation And Validation
- 21. Car-t Cell Therapy Market: Distribution By Key Geographical Regions
- 21.1. Chapter Overview
- 21.2. Key Assumptions And Methodology
- 21.3. Car-t Cell Therapy Market: Distribution By Key Geographical Regions, 2024, 2030 And 2035
- 21.3.1. Car-t Cell Therapy Market In North America: Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 21.3.2. Car-t Cell Therapy Market For Europe: Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 21.3.3. Car-t Cell Therapy Market For Asia-pacific: Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 21.3.4. Car-t Cell Therapy Market For Rest Of The World: Historical Trends (2018-2023) And Future Estimates (2024-2035)
- 21.4. Data Triangulation And Validation
- 22. Car-t Therapy Market, Sales Forecast Of Drugs
- 23. Promotional Analysis
- 23.1. Chapter Overview
- 23.2. Channels Used For Promotional Campaigns
- 23.3. Summary Of Product Website Analysis
- 23.4. Summary Of Patient Support Services And Informative Downloads
- 23.5. Kymriah: Promotional Analysis
- 23.5.1. Drug Overview
- 23.5.2. Product Website Analysis
- 23.5.2.1. Message For Healthcare Professionals
- 23.5.2.2. Message For Patients
- 23.5.2.3. Informative Downloads
- 23.5.3. Patient Support Services
- 23.6. Yescarta: Promotional Analysis
- 23.6.1. Drug Overview
- 23.6.2. Product Website Analysis
- 23.6.2.1. Message For Healthcare Professionals
- 23.6.2.2. Message For Patients
- 23.6.2.3. Informative Downloads
- 23.6.3. Patient Support Services
- 23.7. Tecartus: Promotional Analysis
- 23.7.1. Drug Overview
- 23.7.2. Product Website Analysis
- 23.7.2.1. Message For Healthcare Professionals
- 23.7.2.2. Message For Patients
- 23.7.2.3. Informative Downloads
- 23.7.3. Patient Support Services
- 23.8. Breyanzi: Promotional Analysis
- 23.8.1. Drug Overview
- 23.8.2. Product Website Analysis
- 23.8.2.1. Message For Healthcare Professionals
- 23.8.2.2. Message For Patients
- 23.8.2.3. Informative Downloads
- 23.8.3. Patient Support Services
- 23.9. Abecma: Promotional Analysis
- 23.9.1. Drug Overview
- 23.9.2. Product Website Analysis
- 23.9.2.1. Message For Healthcare Professionals
- 23.9.2.2. Message For Patients
- 23.9.2.3. Informative Downloads
- 23.9.3. Patient Support Services
- 23.10. Carvykti: Promotional Analysis
- 23.10.1. Drug Overview
- 23.10.2. Product Website Analysis
- 23.10.2.1. Message For Healthcare Professionals
- 23.10.2.2. Message For Patients
- 23.10.2.3. Informative Downloads
- 23.10.3. Patient Support Services
- 24. Executive Insights
- 24.1. Chapter Overview
- 24.2. Glycostem Therapeutics
- 24.2.1. Company Snapshot
- 24.2.2. Interview Transcript
- 24.3. Gracell Biotechnologies
- 24.3.1. Company Snapshot
- 24.3.2. Interview Transcript
- 24.4. Txcell
- 24.4.1. Company Snapshot
- 24.4.2 Interview Transcript
- 24.5. Kite Pharma
- 24.5.1. Company Snapshot
- 24.5.2. Interview Transcript
- 24.6. Celyad
- 24.6.1. Company Snapshot
- 24.6.2. Interview Transcript
- 24.7. Waisman Biomanufacturing
- 24.7.1. Company Snapshot
- 24.7.2. Interview Transcript
- 24.8. Theravectys
- 24.8.1. Company Snapshot
- 24.8.2. Interview Transcript
- 24.9. Changhai Hospital
- 24.9.1. Company Snapshot
- 24.9.2. Interview Transcript
- 24.10. Changhai Hospital
- 24.10.1. Company Snapshot
- 24.10.2. Interview Transcript
- 25. Concluding Remarks
- 26. Appendix I: Tabulated Data
- 27. Appendix Ii: List Of Companies And Organizations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
